220 related articles for article (PubMed ID: 16549049)
1. Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells.
Shan BE; Hao JS; Li QX; Tagawa M
Cell Mol Immunol; 2006 Feb; 3(1):47-52. PubMed ID: 16549049
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects produced by transduction of dendritic cells-derived heterodimeric cytokine genes in murine colon carcinoma cells.
Chiyo M; Shimozato O; Iizasa T; Fujisawa T; Tagawa M
Anticancer Res; 2004; 24(6):3763-7. PubMed ID: 15736409
[TBL] [Abstract][Full Text] [Related]
3. T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines.
Tada Y; O-Wang J; Yu L; Shimozato O; Wang YQ; Takiguchi Y; Tatsumi K; Kuriyama T; Takenaga K; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Jun; 10(6):451-6. PubMed ID: 12768190
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
[TBL] [Abstract][Full Text] [Related]
5. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors.
Kawamura K; Bahar R; Natsume W; Sakiyama S; Tagawa M
Cancer Gene Ther; 2002 Jan; 9(1):109-15. PubMed ID: 11916240
[TBL] [Abstract][Full Text] [Related]
6. Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts.
Ugai S; Shimozato O; Kawamura K; Wang YQ; Yamaguchi T; Saisho H; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Mar; 10(3):187-92. PubMed ID: 12637939
[TBL] [Abstract][Full Text] [Related]
7. The secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions and abrogates IL-23-mediated antitumour effects.
Shimozato O; Ugai S; Chiyo M; Takenobu H; Nagakawa H; Wada A; Kawamura K; Yamamoto H; Tagawa M
Immunology; 2006 Jan; 117(1):22-8. PubMed ID: 16423037
[TBL] [Abstract][Full Text] [Related]
8. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects.
Ugai S; Shimozato O; Yu L; Wang YQ; Kawamura K; Yamamoto H; Yamaguchi T; Saisho H; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Oct; 10(10):771-8. PubMed ID: 14502230
[TBL] [Abstract][Full Text] [Related]
9. Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells.
Tasaki K; Yoshida Y; Maeda T; Miyauchi M; Kawamura K; Takenaga K; Yamamoto H; Kouzu T; Asano T; Ochiai T; Sakiyama S; Tagawa M
Cancer Gene Ther; 2000 Feb; 7(2):247-54. PubMed ID: 10770633
[TBL] [Abstract][Full Text] [Related]
10. Preliminary study on mouse interleukin-21 application in tumor gene therapy.
Dou J; Chen G; Wang J; Zhao F; Chen J; Fang X; Tang Q; Chu L
Cell Mol Immunol; 2004 Dec; 1(6):461-6. PubMed ID: 16293216
[TBL] [Abstract][Full Text] [Related]
11. Expression of interleukin-21 and -23 in human esophageal tumors produced antitumor effects in nude mice.
Shan B; Yu L; Shimozato O; Li Q; Tagawa M
Anticancer Res; 2004; 24(1):79-82. PubMed ID: 15015579
[TBL] [Abstract][Full Text] [Related]
12. Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer.
Nakamori M; Iwahashi M; Nakamura M; Ueda K; Zhang X; Yamaue H
Clin Cancer Res; 2003 Jun; 9(6):2357-65. PubMed ID: 12796406
[TBL] [Abstract][Full Text] [Related]
13. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells.
Wang YQ; Ugai S; Shimozato O; Yu L; Kawamura K; Yamamoto H; Yamaguchi T; Saisho H; Tagawa M
Int J Cancer; 2003 Jul; 105(6):820-4. PubMed ID: 12767068
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
15. A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model.
Jack AM; Aydin N; Montenegro G; Alam K; Wallack M
J Surg Res; 2007 May; 139(2):164-9. PubMed ID: 17275030
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-4 gene transduced tumor cells promote a potent tumor-specific Th1-type response in cooperation with interferon-alpha transduction.
Eguchi J; Hiroishi K; Ishii S; Baba T; Matsumura T; Hiraide A; Okada H; Imawari M
Gene Ther; 2005 May; 12(9):733-41. PubMed ID: 15772692
[TBL] [Abstract][Full Text] [Related]
17. Generation of antitumor response by IL-2-transduced JAWS II dendritic cells.
Rossowska J; Pajtasz-Piasecka E; Ryśnik O; Wojas J; Krawczenko A; Szyda A; Duś D
Immunobiology; 2011 Oct; 216(10):1074-84. PubMed ID: 21676487
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic effects of treatment of pancreatic carcinoma by interleukin-23 and apoptotic cell antigen-modified dendritic cell vaccine: experiment with mice].
Tan G; Wang ZY; Yin S
Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(14):943-6. PubMed ID: 16759530
[TBL] [Abstract][Full Text] [Related]
19. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.
Tahara H; Zeh HJ; Storkus WJ; Pappo I; Watkins SC; Gubler U; Wolf SF; Robbins PD; Lotze MT
Cancer Res; 1994 Jan; 54(1):182-9. PubMed ID: 7903204
[TBL] [Abstract][Full Text] [Related]
20. Different antitumor immunity roles of cytokine activated T lymphocytes from naive murine splenocytes and from dendritic cells-based vaccine primed splenocytes: implications for adoptive immunotherapy.
Zhang S; Wang Q; Li WF; Wang HY; Zhang HJ; Zhu JJ
Eksp Onkol; 2004 Mar; 26(1):55-62. PubMed ID: 15112581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
